stockrowTrulieve Cannabis Corp.
TRLV Healthcare Drug Manufacturers Specialty & Generic
Trulieve Cannabis Corp.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, roughly unchanged from fiscal 2024.
- Revenue
- −20.1%
- EPS
- −2,391.1%
- Free cash flow
- +24.5%
- Total debt
- −37.0%
Quarter to September 2026, against a year earlier
Follow TRLV
Alert me
Trulieve Cannabis Corp. (TRLV) EPS (diluted)
Trulieve Cannabis Corp.'s EPS (diluted) for fiscal 2025 was −$0.58, compared with −$0.79 in fiscal 2024. Over the twelve months to 30 June 2026 it was −$2.47. Over the past ten years it has ranged from −$2.28 (fiscal 2023) to $0.53 (fiscal 2020); the current reading is higher than 67% of that period. Trulieve Cannabis Corp. ranks 64th of 75 Drug Manufacturers Specialty & Generic companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$0.58 | — |
| FY2024 | −$0.79 | — |
| FY2023 | −$2.28 | — |
| FY2022 | −$1.34 | — |
| FY2021 | $0.12 | (77.67%) |
| FY2020 | $0.53 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | −$2.10 | — |
| Mar 2026 | $0.01 | — |
| Dec 2025 | −$0.23 | — |
| Sep 2025 | −$0.15 | — |
| 18 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| ANIP ANI Pharmaceuticals, Inc. compare | $5.02 |
| PBH Prestige Consumer Healthcare Inc. compare | $3.24 |
| XERS Xeris Biopharma Holdings, Inc. compare | −$0.05 |
| ALVO Alvotech compare | −$1.24 |
| BCRX BioCryst Pharmaceuticals, Inc. compare | −$1.42 |
| TRLV Trulieve Cannabis Corp. | −$2.47 |
| PRGO Perrigo Company plc compare | −$12.76 |
| RGC Regencell Bioscience Holdings Limited compare | — |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | — |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on TRLV
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement